Turnover Talk: Current Treatment Decisions for Front Line Ovarian Cancer
Discussion of maintenance therapy with PARPi, or bevacizumab, and improvement in progression free survival after front line treatment for advanced high grade epithelial ovarian cancer
Category
  • Turnover Talks
  • Ovary
  • PARPi
Format
Credits